EYA2 and cancer: Patients with tumoral loss of Eya2 expression had significantly worse survival (median survival, 17.2 months) compared to patients whose cancers retained Eya2 expression (24.5 months, P=0.03), but Eya2 loss was not an independent predictor of survival when other factors associated with outcome (such as stage, differentiation, node status) were considered in a multivariate model (data not shown).